Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $6.50 price target on the stock.
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting [Yahoo! Finance]
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem [Yahoo! Finance]
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence [Yahoo! Finance]